Percentages of marrow infiltration by immune effectors before and after DLI
| . | . | Responders . | Nonresponders . | . | ||||
|---|---|---|---|---|---|---|---|---|
| . | Months . | n . | Median (%) . | Range (%) . | n . | Median (%) . | Range (%) . | P (R vs NR) . |
| CD3 | 0 | 19 | 8 | 2.5-20 | 5 | 2.5 | 1-3.5 | .009 |
| 3-6 | 20 | 10.5 | 2.5-25 | 6 | 2.5 | 1-5 | .002 | |
| 9-12 | 17 | 13 | 2.5-70 | 3 | 2.5 | 1-12.5 | .09 | |
| P | P | |||||||
| 0 vs 3-6 | .07 | NS | ||||||
| 0 vs 9-12 | .02 | NS | ||||||
| . | . | Responders . | Nonresponders . | . | ||||
|---|---|---|---|---|---|---|---|---|
| . | Months . | n . | Median (%) . | Range (%) . | n . | Median (%) . | Range (%) . | P (R vs NR) . |
| CD3 | 0 | 19 | 8 | 2.5-20 | 5 | 2.5 | 1-3.5 | .009 |
| 3-6 | 20 | 10.5 | 2.5-25 | 6 | 2.5 | 1-5 | .002 | |
| 9-12 | 17 | 13 | 2.5-70 | 3 | 2.5 | 1-12.5 | .09 | |
| P | P | |||||||
| 0 vs 3-6 | .07 | NS | ||||||
| 0 vs 9-12 | .02 | NS | ||||||
| . | Months . | n . | Median (%) . | Range (%) . | n . | Median (%) . | Range (%) . | P (R vs NR) . |
|---|---|---|---|---|---|---|---|---|
| CD8 | 0 | 19 | 5 | 2.5-20 | 5 | 2.5 | 0.5-3.75 | .009 |
| 3-6 | 20 | 10 | 2.5-20 | 6 | 2.5 | 0.5-4.38 | .002 | |
| 9-12 | 17 | 10 | 2.5-70 | 2 | 1.5 | 0.5-2.5 | .03 | |
| P | P | |||||||
| 0 vs 3-6 | .03 | NS | ||||||
| 0 vs 9-12 | .03 | NS |
| . | Months . | n . | Median (%) . | Range (%) . | n . | Median (%) . | Range (%) . | P (R vs NR) . |
|---|---|---|---|---|---|---|---|---|
| CD8 | 0 | 19 | 5 | 2.5-20 | 5 | 2.5 | 0.5-3.75 | .009 |
| 3-6 | 20 | 10 | 2.5-20 | 6 | 2.5 | 0.5-4.38 | .002 | |
| 9-12 | 17 | 10 | 2.5-70 | 2 | 1.5 | 0.5-2.5 | .03 | |
| P | P | |||||||
| 0 vs 3-6 | .03 | NS | ||||||
| 0 vs 9-12 | .03 | NS |
| . | Months . | n . | Median (%) . | Range (%) . | n . | Median (%) . | Range (%) . | P (R vs NR) . |
|---|---|---|---|---|---|---|---|---|
| CD4 | 0 | 19 | 0 | 0-8 | 5 | 0 | 0-0.5 | .24 |
| 3-6 | 20 | 1.88 | 0-11 | 6 | 0 | 0-2.5 | .11 | |
| 9-12 | 17 | 3 | 0-20 | 3 | 0.5 | 0-12.5 | .99 | |
| P | P | |||||||
| 0 vs 3-6 | .96 | NS | ||||||
| 0 vs 9-12 | .32 | NS |
| . | Months . | n . | Median (%) . | Range (%) . | n . | Median (%) . | Range (%) . | P (R vs NR) . |
|---|---|---|---|---|---|---|---|---|
| CD4 | 0 | 19 | 0 | 0-8 | 5 | 0 | 0-0.5 | .24 |
| 3-6 | 20 | 1.88 | 0-11 | 6 | 0 | 0-2.5 | .11 | |
| 9-12 | 17 | 3 | 0-20 | 3 | 0.5 | 0-12.5 | .99 | |
| P | P | |||||||
| 0 vs 3-6 | .96 | NS | ||||||
| 0 vs 9-12 | .32 | NS |
| . | Months . | n . | Median (%) . | Range (%) . | n . | Median (%) . | Range (%) . | P (R vs NR) . |
|---|---|---|---|---|---|---|---|---|
| CD20 | 0 | 19 | 2.5 | 2-20 | 5 | 2.5 | 0-2.5 | .02 |
| 3-6 | 20 | 5.38 | 1-40 | 6 | 2.5 | 0-6.25 | .04 | |
| 9-12 | 17 | 7.5 | 2.5-20 | 3 | 1 | 0.5-2.5 | .01 | |
| P | P | |||||||
| 0 vs 3-6 | .08 | NS | ||||||
| 0 vs 9-12 | .4 | NS |
| . | Months . | n . | Median (%) . | Range (%) . | n . | Median (%) . | Range (%) . | P (R vs NR) . |
|---|---|---|---|---|---|---|---|---|
| CD20 | 0 | 19 | 2.5 | 2-20 | 5 | 2.5 | 0-2.5 | .02 |
| 3-6 | 20 | 5.38 | 1-40 | 6 | 2.5 | 0-6.25 | .04 | |
| 9-12 | 17 | 7.5 | 2.5-20 | 3 | 1 | 0.5-2.5 | .01 | |
| P | P | |||||||
| 0 vs 3-6 | .08 | NS | ||||||
| 0 vs 9-12 | .4 | NS |
NS, not significant.
Comparisons between patients within response cohorts were analyzed by the Wilcoxon signed-rank test and between responders (R) and nonresponders (NR) by the Wilcoxon exact rank-sum test.
Bold values indicate statistical significance of P < .05.